Human interleukin-4 possesses two distinct sites for receptor activation. A signaHing site, comprising residues near the C-terminus on helix D, determines the efficacy of interleukin-4 signal transduction without affecting the binding to the interleukin-4 receptor a subunit. A complete antagonist and a series of low-efficacy agonist variants of human interleukin-4 could be generated by introducing combinations of two or three negatively charged aspartic acid residues in this site at Human interleukin-4 (IL-4) activates its cognate receptor system by sequential binding to two different receptor subunits. The frrst high-affinity binding step (Kd 100 pM) involves the interaction between IL-4 receptor a subunit (Beckmann et al., 1992 ; Galizzi et al., 1990; Idzerda et al., 1990) and IL-4 amino acid residues located on helices A and C (Kruse et al., 1993; Ramanathan et al., 1993) . The subsequent second binding step involves a signalling site on helix D of IL-4 (Kruse et al., 1992) and a further receptor subunit, which according to recent evidence (Kondo et al., 1993; Russell et al., 1993) is probably the y chain of the IL-2 receptor system, now designated ' Yc· Such a sequential two-step binding mechanism leading to receptor activation suggests a rationale for the design of antagonistic cytokine variants (Cunningham et al., 1991 ; De Vos et aJ., 1992). If the first high-affinity binding site is retained and the second signalling site is either destroyed by Correspondence to W. Sebald, Theodor-Boveri-lnstitut für Biowissenschaften (Biozentrum) der Universität, Physiologische Chemie ll,
Human interleukin-4 (IL-4) activates its cognate receptor system by sequential binding to two different receptor subunits. The frrst high-affinity binding step (Kd 100 pM) involves the interaction between IL-4 receptor a subunit (Beckmann et al., 1992 ; Galizzi et al., 1990; Idzerda et al., 1990) and IL-4 amino acid residues located on helices A and C (Kruse et al., 1993; Ramanathan et al., 1993) . The subsequent second binding step involves a signalling site on helix D of IL-4 (Kruse et al., 1992) and a further receptor subunit, which according to recent evidence (Kondo et al., 1993; Russell et al., 1993) is probably the y chain of the IL-2 receptor system, now designated ' Yc· Such a sequential two-step binding mechanism leading to receptor activation suggests a rationale for the design of antagonistic cytokine variants (Cunningham et al., 1991 ; De Vos et aJ., 1992) . If the first high-affinity binding site is retained and the second signalling site is either destroyed by mutations (Fuh et al., 1992; Kruse et al., 1992) or blocked by monoclonal antibodies (Reusch et al., 1994) , the oligomerisation process stops at the Ievel of the unproductive 1 : 1 complex between the cytokine and the first receptor subunit. The signalling site of human IL-4 comprises side chains of Arg121, Tyr124 and Ser125. Previous results have shown that variants [R121D1IL-4 and [S125D1IL-4 have approximately 30% partial agonist activity and variant [Y124D]IL-4 has less than 1% partial agonist activity for T-cell proliferation compared to wild-type IL-4. High-affinity binding to the IL-4 receptor a subunit is retained in these variants as shown by in vitro binding experiments (Kruse et al., 1992) . According to high-resolution three-dimensional NMR spectroscopy , unpublished results) the conformational changes produced by replacement of IL-4 Tyr124 by glycine or aspartic acid are confined to the immediate environment of the side chain. No changes in the secondary or tertiary structures of these IL-4 variants compared to the wild-type protein could be detected.
The variant [Y124D]IL-4 behaves as a complete antagonist for IL-4-dependent T-cell proliferation in vitro. It has, however, a partial agonist activity of up to 40% for the induction of CD23 expression in B-cells. The reason for this difference is not clear. Therefore, it was investigated as to how far this residual partial agonist activity on B-cells can be abolished by introducing combinations of two or three aspartic acid residues at positions 121, 124 and 125. More than additive effects could be observed if double-mutant and triple-mutant proteins were analysed for partial agonist and antagonist activity in B-cells and T-cells. Zurawski et al., 1993) . Furthermore, a monoclonal antibody XZ/45 raised against the recombinant extracellular domajn of the IL-4 receptor was also found to inhibit both IL-4-dependent and IL-13-dependent B-cell responses. These results provide independent conclusive evidence that the cloned IL-4 receptor a. subunit is an essential constituent of the IL-13 receptor system.
MATERIALS AND METHODS
Recombinant human IL-13, produced and purified from Escherichia coli, was from IC Chemikalien GmbH.
Human IL-4 variants were generated by in vitro mutagenesis, expressed in E. coli, renatured and purified (Kruse et al., 1991 (Kruse et al., , 1992 Monoclonal antibodies to IL-4Rex, the extracellular domain of the IL-4 receptor a. chain, were generated by standard procedures using recombinant human IL-4Rex produced in Chinese hamster ovary cells as antigen (Kruse et al., 1993) . Assays for competition with radioligand binding, human T-cell proliferation, and induction in B-cells of CD23 (Fes RU), the low-affinity receptor for lgE, have been described (Kruse et al., 1992; Kruse et al., 1993) . 
Statistical evaluations

RESULTS
Binding properties of double and triple 
mutant proteins
In previous experiments (Kruse et al., 1992) , the variants [R121D]IL-4, [Y124D]IL-4 and [S125D]IL-4 were shown to retain high-affinity binding to the IL-4 receptor a. chain. Tab1e 1 shows that the occurrence of two or three negatively charged residues in the double and triple variants does not significantly alter the binding to the recombinant extracellular domain of the IL-4 receptor a subunit (IL-4Rex). The Kd values are in the range 50-300 pM. These values are similar to those displayed by the single mutants (Kruse et al., 1993) . These findings are consistent with recent structural data showing that the conformation of the IL-4 protein is not altered by the amino acid replacement causing only local perturbations at the site of the changed side chain. Thus, it is reasonable to conclude that for the vru.iants with multiple changes described in this study, the secondary and tertiary structures also remain grossly unaltered. (Kruse et al., 1992) . The concentration of 125 1-labeled IL-4 was 0.59 nM in experiment 1 and 0.32 nM in experiment 2. The Kd value for IL-4 of 100 pM was determined from the dose-dependence of receptor saturation after correcting for unspecific binding (Kruse et al., 1993 Biological activities of variants as determined by T-cell proliferation
All variants in Table 2 failed to stimulate T-cell proliferation significantly above background Ievels. (Table 4 ). The maximal Ievel of inhibition obtainable is determined by the specific partial agonist activity of each variant (Table 3) Inhibition of IL-13-induced CD23 expression CD23 can also be induced in human B-cells upon stimulation with IL-13 (McKenzie et al., 1993; Minty et al., 1993; Punnonen et al., 1993) . The maximal responses are lower, however, than those obtainable with IL-4 (Table 5) . At Saturation Ievels of IL-13, the number of CD23-positive cells is only approximately 67% the number of cells inducible by IL-4, and the mean CD23 content is approximately 33% (Table 5). This suggests that only a subpopulation of IL-4-responsive B-cells is also responsive to IL-13, and, furthermore, that even in the IL-13-responsive subpopulation the IL-13-inducible CD23 content is lower (less than 50%). The EC 50 values of IL-13 are higher than those of IL-4. In the experiment described in Table 5 , differences between EC 50 values were more than tenfold. The variant [R121D, Table 3 . Partialagonist activities of IL-4 variants on CD23 induction in B-cells. A background value of 6.6% (10.1 %) CD23-positive cells and of 3.5% (2.9%) mean CD23 content measured without IL-4 was subtracted from all numbers in experiment 1 (experiment 2). The EC~o of IL-4 for induction of CD23-positive B-cells was 1 pM (3 pM) and of mean CD23 content 6 pM (18 pM) during experiment 1 (experiment 2 Table 5 .
Monoclonal antibody X2/45 directed against IL-4Rex inhibits both IL·4·induced and IL-13·induced CD23 expression in B-cells The monoclonal antibody (mAb) X2/45 was prepared by immunizing mice with a recombinant extracel1ular domain Table 6 (experiment 2). 3.1 IL-4R..x of the IL-4 receptor a subunit (Kruse et al., 1993) . X2/45 interferes with IL-4 binding and inhibits IL-4-induced T-cell proliferation with a Ki value of 20 nM. X2/45 specifically recognizes the IL-4 receptor a chain on the cell surface as was shown by flow cytometry (Reusch, P., unpublished results). As demonstrated in Fig. 4 and Table 6 , mAb X2/45 inhibits IL-13-dependent CD23 induction in B-cells as efficiently as the IL-4-dependent response. The activity of both interleukins can be inhibited to background Ievels and the Ki values are in the same range (3-12 nM). An isotype matched control mAb (anti-CD4) had no effect at comparable concentrations. This indicates that IL-4R..x is necessary for IL-4 and for IL-13 activity. . The experiments described in Table  7 extend these findings employing variant [R121D, Y124D]IL-4. ln addition, the inhibitory action of anti IL4Rex mAb X2/45 on both IL-4 and IL-13 activity is demonstrated. In TF-1 cells, the maximal response for IL-13 (Rmax) was only 20-25% of the Rmax produced by IL-4. The EC 50 value of IL-13 was 4-8-fold higher than the EC 50 value of IL-4. The activity of both cytokines could be inhibited by variant [R121D,Y124D]IL-4 with a Ki value of 40-80 pM. The very high-affinity binding site on TF-1 cells for human IL-4 (Kd less than 10 pM, see Zurawski et al., 1993) could not be detected during competitive radioligand binding. A Kd of 100 to 150 pM was determined for IL-4 binding in the presence of 125 pM 125 1-labeled IL-4 as weil as in the presence of 2.5 pM 125 1-labeled IL-4 (data not shown).
DISCUSSION
Extending our previous studies on IL-4 variants, the present results demonstrate that it is feasible to rationalJy design a second generation of human IL-4 antagonists/partial agonists displaying extremely low efficacy. Furthennore, these data together with the data on the inhibitory activity of anti IL-4Re;\ monoclonal antibodies yields information on the functional interaction of IL-4 with its receptor subunits and on the essential role of the established IL-4 receptor a subunit during both IL-4-dependent and IL-13-dependent responses in T-cells and B-cells.
The loss of signaHing activity (efficacy) in multiple IL-4 variants appears to be caused by the defective signalling site comprising the juxtaposed amino acid side chains at positions 121, 124 and 125 of helix D. [Allosteric effects due to the amino acid replacement arenot detected by high-resolution three-dimensional NMR spectroscopy Müller, unpublished results) and the binding affinity to IL-4R..x remains largely unaltered]. The signalling activity of this site depends on a hydrophobic patch provided by Tyr124 ( or another I arge hydrophobic side chain) and is weakened specifically if the negatively charged side chain of aspartic acid is present (Demchuk et al., 1994) . The occurrence at positions 121 and 125 of small, large hydrophobic, polar, or glutamyl residues introduced at this position has no or only small effects (Kruse N. and Sebald, W., unpublished results) In the double variants, the effect of the individual amino acid replacements may be more than additive. The loss of potency in variant [R121D,S125D]IL-4 is more than 100-fold. The additive loss would have been approximately tenfold. In variant [R121D,Y124D]IL-4, no agonist activity could be measured. This indicates a more than 2000-fold reduced potency compared to IL-4 (considering the background and the sensitivity oftheB-eeil assay). This is again slightly above the value expected from the added effects in [R121D]IL-4 (approximately three-fold) and [Y124D]IL-4 (greater than 100 fold). It has been discussed (Rigley et al., 1991) that B-cells contain two different IL-4 receptors as one possibility to explain the different sensitivities to IL-4 and anti-CD19 mAb and the different intracellular signalling requirement for induction of surface IgM and mean CD23 content in human tonsillar B-cells. The present study did not analyse IL-4-dependent surface IgM expression in B-cells. The inhibition by anti IL-4Rex mAb X2/45 of both the very sensitive induction of CD23-positive B-cells (EC 50 1-3 pM in these experiments) and the mean CD23 content in B-cells (EC 50 3-13 pM) indicate however, that the IL-4 receptor a subunit is involved in both of these B-cell responses. Thus, it is a distinct possibility that these graded sensitivities of IL-4 responses result from different post-receptor signalling steps.
In previous sturlies it has been demonstrated (Aversa et al., It is a reasonable working hypothesis that the signalling site of human IL-4, i.e. the amino acid side chains at positions 121, 124 and 125 interact with the common y chain, which has been identified first in the IL-2 receptor system and which has been later established to be also a constitutent of the IL-4 and IL-7 receptor systems (Kondo et al., 1993; Russell et al., 1993; Kondo et al., 1994) . Actually, conspicuous similarities can be detected if the corresponding surface areas of human IL-4 and IL-2 are compared (Müller, T., unpublished results). It is unknown at this time whether or not the common y chain also functions in the IL-13 receptor system. The C-terminus of human and murine IL-13 exhibits · some similarities to the signalling site of IL-4, although one published alignment postulates the insertion of a glycine residue at the corresponding IL-13 sequence. It is tempting to speculate that the IL-13 receptor system uses both the IL-4 receptor a subunit and the common y chain and that IL-13 specificity is determined by an additional third chain similar to the ciliary-neutrophic-factor receptor system (Davis et al., 1993; Kishimoto et al., 1994 formed by the human IL-4 antagonists ) might be a 1:1 complex between the IL-4 receptor a subunit and the IL-4 antagonist, which cannot associate further due to the defective signaHing site with the common y chain to form the functional IL-4 receptor or with the common y chain plus the IL-13-binding protein to form the functional IL-13 receptor. 
